Cancer Research & Development


Cancer continues to be a formidable disease with an overall drug commercialization success rate of only 5–8%. This high failure rate is often attributed to a deficit
between pre-clinical knowledge and clinical efficacy and illustrates the need for
better translatability of preclinical research to the population of patients likely to
benefit. Cancer is an extraordinarily complex disease involving, a heterogeneous mix
of genetically mercurial cancer cells, stroma, and microenvironment across at least
200 different cancer types. Even with a specific cancer type, heterogeneity within
patients impairs clinical development. Thus, the clinical challenges are substantial
—to produce a meaningful regression or survival benefit based on targeting an
important aspect or aspects of this complex biology.